These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35142611)

  • 1. Performance of apparent diffusion coefficient values and ratios for the prediction of prostate cancer aggressiveness across different MRI acquisition settings.
    Karaarslan E; Altan Kus A; Alis D; Karaarslan UC; Saglican Y; Argun OB; Kural AR
    Diagn Interv Radiol; 2022 Jan; 28(1):12-20. PubMed ID: 35142611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
    Bajgiran AM; Mirak SA; Sung K; Sisk AE; Reiter RE; Raman SS
    AJR Am J Roentgenol; 2019 Sep; 213(3):W134-W142. PubMed ID: 31216201
    [No Abstract]   [Full Text] [Related]  

  • 3. The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer.
    Nowak J; Malzahn U; Baur AD; Reichelt U; Franiel T; Hamm B; Durmus T
    Acta Radiol; 2016 Jan; 57(1):107-14. PubMed ID: 25505225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI of the Prostate With and Without Endorectal Coil at 3 T: Correlation With Whole-Mount Histopathologic Gleason Score.
    Dhatt R; Choy S; Co SJ; Ischia J; Kozlowski P; Harris AC; Jones EC; Black PC; Goldenberg SL; Chang SD
    AJR Am J Roentgenol; 2020 Jul; 215(1):133-141. PubMed ID: 32160050
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score.
    Donati OF; Afaq A; Vargas HA; Mazaheri Y; Zheng J; Moskowitz CS; Hricak H; Akin O
    Clin Cancer Res; 2014 Jul; 20(14):3705-11. PubMed ID: 24850842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer.
    Wang X; Tu N; Qin T; Xing F; Wang P; Wu G
    AJR Am J Roentgenol; 2018 Oct; 211(4):797-804. PubMed ID: 30085835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced MR imaging for assessment of tumor aggressiveness in prostate cancer at 3T.
    Fukunaga T; Tamada T; Kanomata N; Takeuchi M; Ueda Y; Miyaji Y; Kido A; Yamamoto A; Sone T
    Magn Reson Imaging; 2021 Nov; 83():152-159. PubMed ID: 34454006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
    Cindil E; Oner Y; Sendur HN; Ozdemir H; Gazel E; Tunc L; Cerit MN
    Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of diagnostic performance between diffusion kurtosis imaging parameters and mono-exponential ADC for determination of clinically significant cancer in patients with prostate cancer.
    Park H; Kim SH; Lee Y; Son JH
    Abdom Radiol (NY); 2020 Dec; 45(12):4235-4243. PubMed ID: 32965517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the aggressiveness of peripheral zone prostate cancer using a fractional order calculus diffusion model.
    Li Z; Dan G; Tammana V; Johnson S; Zhong Z; Rabiee B; Zhou XJ; L Xie K
    Eur J Radiol; 2021 Oct; 143():109913. PubMed ID: 34464907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Stratification of Prostate Cancer Using the Combination of Histogram Analysis of Apparent Diffusion Coefficient Across Tumor Diffusion Volume and Clinical Information: A Pilot Study.
    Zhang Z; Xu H; Xue Y; Li J; Ye Q
    J Magn Reson Imaging; 2019 Feb; 49(2):556-564. PubMed ID: 30173421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.
    Hötker AM; Mazaheri Y; Aras Ö; Zheng J; Moskowitz CS; Gondo T; Matsumoto K; Hricak H; Akin O
    AJR Am J Roentgenol; 2016 Apr; 206(4):756-63. PubMed ID: 26900904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of multiparametric MRI parameters for Gleason score and cellularity metrics of prostate cancer in different zones: a quantitative comparison.
    Gao J; Zhang Q; Zhang C; Chen M; Li D; Fu Y; Lv X; Zhang B; Guo H
    Clin Radiol; 2019 Nov; 74(11):895.e17-895.e26. PubMed ID: 31337490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer aggressive prediction: preponderant diagnostic performances of intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) beyond ADC at 3.0 T scanner with gleason score at final pathology.
    Shan Y; Chen X; Liu K; Zeng M; Zhou J
    Abdom Radiol (NY); 2019 Oct; 44(10):3441-3452. PubMed ID: 31144091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.
    Thörmer G; Otto J; Horn LC; Garnov N; Do M; Franz T; Stolzenburg JU; Moche M; Kahn T; Busse H
    Acta Radiol; 2015 Jan; 56(1):121-8. PubMed ID: 24504488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ
    BJU Int; 2017 Jan; 119(1):57-66. PubMed ID: 26823024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Exponential ADC (eADC) and Computed DWI (cDWI) for the Detection of Prostate Cancer.
    Sprinkart AM; Marx C; Träber F; Block W; Thomas D; Schild H; Kukuk GM; Mürtz P
    Rofo; 2018 Aug; 190(8):758-766. PubMed ID: 30045400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age.
    Tamada T; Prabhu V; Li J; Babb JS; Taneja SS; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Jun; 42(6):1744-1751. PubMed ID: 28161826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.